RadNet, Inc. (RDNT)

NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-23

$70.34+0.11%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge RadNet, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	670.63M
EPS	—	0.271
FY 2026 · Annual
Revenue	—	2.51B
EPS	—	0.514
EBITDA	$335M–$348Mnon-GAAP	—
Free cash flow	$105M–$115M	—
R&D	$17M–$19M	—
FY 2027 · Annual
Revenue	—	2.78B
EPS	—	0.887

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cash from operations improves	The company raised free cash flow guidance to $122 million for 2026.	Intact	cash from operations falls below $70 million next year	Cash from operations: $87.76M FY2026-Q2; GAAP. Published target: >= $78 million cash from operations. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 10, 202687,760,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Management stated this priority in 3 quarters including 2025-Q4, 2026-Q1, and 2026-Q2. Free Cash Flow guidance for the Imaging Center segment was revised upwards from $105 - $115 million to $115 - $125 million in 2026. Cash from operating activities was $78.97 million in 2026-Q1 and $84.16 million in 2025-Q4, showing stable cash generation. The trajectory is delivering with improved guidance reflecting operational cash flow strength. Delivery assessment Oct 24, 2026
Free cash flow meets raised guidance	The company raised free cash flow guidance to $122 million for 2026.	Intact	free cash flow falls below $112 million in 2026	Free cash flow: $17.828M FY2026-Q2; GAAP. Published target: Free cash flow >= $122 million in 2026. Target period ends 2026-12-31; this observation covers 2026-Q2. Source published Aug 10, 202617,828,000 USD · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Management stated this priority in 3 quarters including 2025-Q4, 2026-Q1, and 2026-Q2. Free Cash Flow guidance for the Imaging Center segment was revised upwards from $105 - $115 million to $115 - $125 million in 2026. Cash from operating activities was $78.97 million in 2026-Q1 and $84.16 million in 2025-Q4, showing stable cash generation. The trajectory is delivering with improved guidance reflecting operational cash flow strength. Delivery assessment Oct 24, 2026
Operating income improves from losses	A primary condition in RadNet, Inc.'s published investment case. The stated target is Operating income improves to positive territory.	Improving	operating income remains negative or worsens over next year	Operating income: $39.468M FY2026-Q2; GAAP. Published target: Operating income improves to positive territory. Target period is not explicitly aligned with this observation. Source published Aug 10, 202639,468,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 41b30fdc-5800-4a64-9aa6-d32bbd885abf. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue grows through strategic acquisitions	RadNet grows revenue 22% yearly by buying strategic businesses like Gleamer SAS.	Intact	YoY revenue growth falls below ~18% next year	Revenue growth: 24.99% FY2026-Q2; GAAP. Published target: >=22% YoY revenue growth. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 10, 202624.986452 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 41b30fdc-5800-4a64-9aa6-d32bbd885abf. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 quarters including 2026-Q1, Q2, and 2025-Q4. Total Company Revenue grew 25.0% from $498.2 million in 2025-Q2 to $622.7 million in 2026-Q2. Digital Health Annual Recurring Revenue nearly doubled from $53.5 million in 2025-Q2 to $105.5 million in 2026-Q2, with management expecting ARR to approach or exceed $140 million by end of 2026. The trajectory is delivering with strong growth driven by the Gleamer acquisition and Digital Health expansion. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

Unavailable → Unavailable · observed estimates

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 4
2026-07-25	Unavailable	Unavailable	3 / 4
2026-07-26	Unavailable	Unavailable	3 / 4
2026-07-27	$0.94	$2,744,031,600	6 / 5
2026-07-28	$0.94	$2,744,031,600	6 / 5
2026-07-29	$0.94	$2,744,031,600	6 / 5
2026-07-30	Unavailable	Unavailable	3 / 4
2026-07-31	$0.94	$2,744,031,600	6 / 5
2026-08-01	Unavailable	Unavailable	3 / 4
2026-08-02	$0.94	$2,744,031,600	6 / 5
2026-08-03	$0.94	$2,744,031,600	6 / 5
2026-08-04	$0.94	$2,744,031,600	6 / 5
2026-08-05	Unavailable	Unavailable	3 / 4
2026-08-06	$0.94	$2,744,031,600	6 / 5
2026-08-08	$0.94	$2,744,031,600	6 / 5
2026-08-09	Unavailable	Unavailable	3 / 4
2026-08-10	$0.94	$2,744,031,600	6 / 5
2026-08-12	$0.91	$2,759,633,800	6 / 5
2026-08-13	Unavailable	Unavailable	3 / 4
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	3 / 4
2026-08-16	Unavailable	Unavailable	3 / 4
2026-08-17	Unavailable	Unavailable	3 / 4
2026-08-18	Unavailable	Unavailable	3 / 4
2026-08-19	Unavailable	Unavailable	3 / 4
2026-08-20	Unavailable	Unavailable	3 / 4
2026-08-21	Unavailable	Unavailable	3 / 4
2026-08-22	Unavailable	Unavailable	3 / 4
2026-08-23	Unavailable	Unavailable	3 / 4
2026-08-24	Unavailable	Unavailable	3 / 4
2026-08-25	Unavailable	Unavailable	3 / 4
2026-08-26	Unavailable	Unavailable	3 / 4
2026-08-27	Unavailable	Unavailable	3 / 4
2026-08-28	Unavailable	Unavailable	3 / 4
2026-08-29	Unavailable	Unavailable	4 / 4
2026-08-30	Unavailable	Unavailable	4 / 4
2026-08-31	Unavailable	Unavailable	4 / 4
2026-09-01	Unavailable	Unavailable	4 / 4
2026-09-02	Unavailable	Unavailable	4 / 4
2026-09-03	Unavailable	Unavailable	4 / 4
2026-09-04	Unavailable	Unavailable	4 / 4
2026-09-05	Unavailable	Unavailable	4 / 4
2026-09-06	Unavailable	Unavailable	4 / 4
2026-09-07	Unavailable	Unavailable	4 / 4
2026-09-08	Unavailable	Unavailable	4 / 4
2026-09-09	Unavailable	Unavailable	4 / 4
2026-09-10	Unavailable	Unavailable	4 / 4
2026-09-11	Unavailable	Unavailable	4 / 4
2026-09-12	Unavailable	Unavailable	4 / 4
2026-09-13	Unavailable	Unavailable	4 / 4
2026-09-14	Unavailable	Unavailable	4 / 4
2026-09-15	Unavailable	Unavailable	4 / 4
2026-09-16	Unavailable	Unavailable	4 / 4
2026-09-17	Unavailable	Unavailable	4 / 4
2026-09-18	Unavailable	Unavailable	4 / 4
2026-09-19	Unavailable	Unavailable	4 / 4
2026-09-20	Unavailable	Unavailable	4 / 4
2026-09-21	Unavailable	Unavailable	4 / 4
2026-09-22	Unavailable	Unavailable	4 / 4
2026-09-23	Unavailable	Unavailable	4 / 4
2026-09-24	Unavailable	Unavailable	4 / 4
2026-09-25	Unavailable	Unavailable	4 / 4
2026-09-26	Unavailable	Unavailable	4 / 4
2026-09-27	Unavailable	Unavailable	4 / 4
2026-09-28	Unavailable	Unavailable	4 / 4
2026-09-29	Unavailable	Unavailable	4 / 4
2026-09-30	Unavailable	Unavailable	4 / 4
2026-10-01	Unavailable	Unavailable	4 / 4
2026-10-02	Unavailable	Unavailable	4 / 4
2026-10-03	Unavailable	Unavailable	4 / 4
2026-10-04	Unavailable	Unavailable	4 / 4
2026-10-05	Unavailable	Unavailable	4 / 4
2026-10-06	Unavailable	Unavailable	4 / 4
2026-10-07	Unavailable	Unavailable	4 / 4
2026-10-08	Unavailable	Unavailable	4 / 4
2026-10-09	Unavailable	Unavailable	4 / 4
2026-10-10	Unavailable	Unavailable	4 / 4
2026-10-11	Unavailable	Unavailable	4 / 4
2026-10-12	Unavailable	Unavailable	4 / 4
2026-10-13	Unavailable	Unavailable	4 / 4
2026-10-14	Unavailable	Unavailable	4 / 4
2026-10-15	Unavailable	Unavailable	4 / 4
2026-10-16	Unavailable	Unavailable	4 / 4
2026-10-17	Unavailable	Unavailable	4 / 4
2026-10-18	Unavailable	Unavailable	4 / 4
2026-10-19	Unavailable	Unavailable	4 / 4
2026-10-20	Unavailable	Unavailable	4 / 4
2026-10-21	Unavailable	Unavailable	4 / 4
2026-10-22	Unavailable	Unavailable	4 / 4
2026-10-23	Unavailable	Unavailable	4 / 4
2026-10-24	Unavailable	Unavailable	4 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	8	0	0
2026-06-01	8	0	0
2026-07-01	8	0	0
2026-08-01	8	0	0
2026-09-01	8	0	0
2026-10-01	8	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cash from operations improvesCash from operations: $87.76M
Free cash flow meets raised guidanceFree cash flow: $17.828M
Operating income improves from lossesOperating income: $39.468M
Revenue grows through strategic acquisitionsRevenue growth: 24.99%

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.7%Typical daily move · historical

Downside history

-38.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

RadNet, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-focused healthcare business with acquisition and digital health expansion driving recent results. The long-term thesis is intact, though the overall signal has shifted from mildly favorable to mixed and the business remains loss-making.

What's priced into RadNet, Inc.

The valuation evidence is mixed: one measure shows RDNT as cheap versus peers, while another indicates a 71% premium to peers. The expectations gap is positive, but the evidence does not explain its scale; the priced-in assessment labels the valuation concern unjustified and overall fragility low.

What the fundamentals likely do

Near-term results show strong revenue growth, higher adjusted EBITDA, and increased 2026 free cash flow guidance for the Imaging Center segment. Digital Health annual recurring revenue, or expected yearly subscription revenue, nearly doubled year over year, while management’s margin progress has been modest. Near-term risk is elevated despite a low estimated miss probability, as earnings surprises have been erratic and trending down.

What RadNet, Inc. hinges on

The multi-year case depends on acquisitions and Digital Health expansion continuing to support revenue growth while cash flow and margins improve. A guidance cut after the recent increase would damage confidence, while weaker employment data could weigh on cyclical healthcare businesses. Continued strong results and guidance from healthcare peers could support sector momentum.

Bottom line

Over the next 1 to 3 years, RDNT’s long-term thesis rests on converting fast growth into steadier cash generation and better margins. Strong recent performance supports the case, but losses, execution risk, and mixed valuation signals remain important. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	670.63M
EPS	—	0.271
FY 2026 · Annual
Revenue	—	2.51B
EPS	—	0.514
EBITDA	$335M–$348Mnon-GAAP	—
Free cash flow	$105M–$115M	—
R&D	$17M–$19M	—
FY 2027 · Annual
Revenue	—	2.78B
EPS	—	0.887

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

Unavailable → Unavailable · observed estimates

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 4
2026-07-25	Unavailable	Unavailable	3 / 4
2026-07-26	Unavailable	Unavailable	3 / 4
2026-07-27	$0.94	$2,744,031,600	6 / 5
2026-07-28	$0.94	$2,744,031,600	6 / 5
2026-07-29	$0.94	$2,744,031,600	6 / 5
2026-07-30	Unavailable	Unavailable	3 / 4
2026-07-31	$0.94	$2,744,031,600	6 / 5
2026-08-01	Unavailable	Unavailable	3 / 4
2026-08-02	$0.94	$2,744,031,600	6 / 5
2026-08-03	$0.94	$2,744,031,600	6 / 5
2026-08-04	$0.94	$2,744,031,600	6 / 5
2026-08-05	Unavailable	Unavailable	3 / 4
2026-08-06	$0.94	$2,744,031,600	6 / 5
2026-08-08	$0.94	$2,744,031,600	6 / 5
2026-08-09	Unavailable	Unavailable	3 / 4
2026-08-10	$0.94	$2,744,031,600	6 / 5
2026-08-12	$0.91	$2,759,633,800	6 / 5
2026-08-13	Unavailable	Unavailable	3 / 4
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	3 / 4
2026-08-16	Unavailable	Unavailable	3 / 4
2026-08-17	Unavailable	Unavailable	3 / 4
2026-08-18	Unavailable	Unavailable	3 / 4
2026-08-19	Unavailable	Unavailable	3 / 4
2026-08-20	Unavailable	Unavailable	3 / 4
2026-08-21	Unavailable	Unavailable	3 / 4
2026-08-22	Unavailable	Unavailable	3 / 4
2026-08-23	Unavailable	Unavailable	3 / 4
2026-08-24	Unavailable	Unavailable	3 / 4
2026-08-25	Unavailable	Unavailable	3 / 4
2026-08-26	Unavailable	Unavailable	3 / 4
2026-08-27	Unavailable	Unavailable	3 / 4
2026-08-28	Unavailable	Unavailable	3 / 4
2026-08-29	Unavailable	Unavailable	4 / 4
2026-08-30	Unavailable	Unavailable	4 / 4
2026-08-31	Unavailable	Unavailable	4 / 4
2026-09-01	Unavailable	Unavailable	4 / 4
2026-09-02	Unavailable	Unavailable	4 / 4
2026-09-03	Unavailable	Unavailable	4 / 4
2026-09-04	Unavailable	Unavailable	4 / 4
2026-09-05	Unavailable	Unavailable	4 / 4
2026-09-06	Unavailable	Unavailable	4 / 4
2026-09-07	Unavailable	Unavailable	4 / 4
2026-09-08	Unavailable	Unavailable	4 / 4
2026-09-09	Unavailable	Unavailable	4 / 4
2026-09-10	Unavailable	Unavailable	4 / 4
2026-09-11	Unavailable	Unavailable	4 / 4
2026-09-12	Unavailable	Unavailable	4 / 4
2026-09-13	Unavailable	Unavailable	4 / 4
2026-09-14	Unavailable	Unavailable	4 / 4
2026-09-15	Unavailable	Unavailable	4 / 4
2026-09-16	Unavailable	Unavailable	4 / 4
2026-09-17	Unavailable	Unavailable	4 / 4
2026-09-18	Unavailable	Unavailable	4 / 4
2026-09-19	Unavailable	Unavailable	4 / 4
2026-09-20	Unavailable	Unavailable	4 / 4
2026-09-21	Unavailable	Unavailable	4 / 4
2026-09-22	Unavailable	Unavailable	4 / 4
2026-09-23	Unavailable	Unavailable	4 / 4
2026-09-24	Unavailable	Unavailable	4 / 4
2026-09-25	Unavailable	Unavailable	4 / 4
2026-09-26	Unavailable	Unavailable	4 / 4
2026-09-27	Unavailable	Unavailable	4 / 4
2026-09-28	Unavailable	Unavailable	4 / 4
2026-09-29	Unavailable	Unavailable	4 / 4
2026-09-30	Unavailable	Unavailable	4 / 4
2026-10-01	Unavailable	Unavailable	4 / 4
2026-10-02	Unavailable	Unavailable	4 / 4
2026-10-03	Unavailable	Unavailable	4 / 4
2026-10-04	Unavailable	Unavailable	4 / 4
2026-10-05	Unavailable	Unavailable	4 / 4
2026-10-06	Unavailable	Unavailable	4 / 4
2026-10-07	Unavailable	Unavailable	4 / 4
2026-10-08	Unavailable	Unavailable	4 / 4
2026-10-09	Unavailable	Unavailable	4 / 4
2026-10-10	Unavailable	Unavailable	4 / 4
2026-10-11	Unavailable	Unavailable	4 / 4
2026-10-12	Unavailable	Unavailable	4 / 4
2026-10-13	Unavailable	Unavailable	4 / 4
2026-10-14	Unavailable	Unavailable	4 / 4
2026-10-15	Unavailable	Unavailable	4 / 4
2026-10-16	Unavailable	Unavailable	4 / 4
2026-10-17	Unavailable	Unavailable	4 / 4
2026-10-18	Unavailable	Unavailable	4 / 4
2026-10-19	Unavailable	Unavailable	4 / 4
2026-10-20	Unavailable	Unavailable	4 / 4
2026-10-21	Unavailable	Unavailable	4 / 4
2026-10-22	Unavailable	Unavailable	4 / 4
2026-10-23	Unavailable	Unavailable	4 / 4
2026-10-24	Unavailable	Unavailable	4 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings